We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Puma Biotech (PBYI - Free Report) . Shares have lost about 44% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Puma Biotech due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Puma Biotech Q4 Earnings & Revenues Beat
Puma Biotech incurred a loss of 29 cents per share in the fourth quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 48 cents as well as the year-ago loss of 80 cents per share.
The loss per share includes an impact of stock-based compensation expense. Excluding such impact, adjusted earnings per share were 1 cent per share versus a loss of 32 cents in the year-ago quarter.
Total revenues consisted of net product revenues from the sales of Nerlynx, license and royalty revenues. In the fourth quarter of 2019, total revenues were $62.9 million, comprising $58.7 million of product revenues from Nerlynx, $0.2 million of royalty revenues from licensing partners and license revenues of $4.0 million. Sales beat the Zacks Consensus Estimate of $57.0 million but were lower than the year-ago figure of $71.1 million.
Quarter in Detail
Sales of Nerlynx declined 3.9% year over year but rose 9.7% on a sequential basis. Nerlynx’s bottle volumes rose 5% sequentially in the quarter. However, new prescriptions declined 16.5% sequentially while total prescription declined 3.3% in the quarter due to lower patient enrolments during the Christmas holiday season.
Total operating costs in the quarter were $71.6 million, down 20.2% year over year.
Research and development expenses (including for stock-based compensation expense) were $31.3 million in the quarter, down 23.7% from the year-ago period.
Selling, general and administrative expenses (including for stock-based compensation expense) declined 21.3% year over year to $30.2 million.
As of Dec 31, 2019, Puma Biotech had cash and cash equivalents of $111.6 million compared with $165.4 million as of Dec 31, 2018.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Puma Biotech (PBYI - Free Report) . Shares have lost about 44% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Puma Biotech due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Puma Biotech Q4 Earnings & Revenues Beat
Puma Biotech incurred a loss of 29 cents per share in the fourth quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 48 cents as well as the year-ago loss of 80 cents per share.
The loss per share includes an impact of stock-based compensation expense. Excluding such impact, adjusted earnings per share were 1 cent per share versus a loss of 32 cents in the year-ago quarter.
Total revenues consisted of net product revenues from the sales of Nerlynx, license and royalty revenues. In the fourth quarter of 2019, total revenues were $62.9 million, comprising $58.7 million of product revenues from Nerlynx, $0.2 million of royalty revenues from licensing partners and license revenues of $4.0 million. Sales beat the Zacks Consensus Estimate of $57.0 million but were lower than the year-ago figure of $71.1 million.
Quarter in Detail
Sales of Nerlynx declined 3.9% year over year but rose 9.7% on a sequential basis. Nerlynx’s bottle volumes rose 5% sequentially in the quarter. However, new prescriptions declined 16.5% sequentially while total prescription declined 3.3% in the quarter due to lower patient enrolments during the Christmas holiday season.
Total operating costs in the quarter were $71.6 million, down 20.2% year over year.
Research and development expenses (including for stock-based compensation expense) were $31.3 million in the quarter, down 23.7% from the year-ago period.
Selling, general and administrative expenses (including for stock-based compensation expense) declined 21.3% year over year to $30.2 million.
As of Dec 31, 2019, Puma Biotech had cash and cash equivalents of $111.6 million compared with $165.4 million as of Dec 31, 2018.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.